Carnosine-synthetase inhibition by β-alanine analogues

A number of β-alanine analogues were tested for their ability to inhibit carnosine-synthetase from rat and chick skeletal muscle. Of the analogues tested, 3-aminopropanesulfonic acid (APS) was the most effective inhibitor of enzyme from either source. 5-Aminovaleric acid (5-AV) also inhibited the enzyme from rat, but did not inhibit the enzyme from chick. 2-Aminoethylphosphonic acid and o-phosphoethanolamine had a small amount of inhibitory activity on both rat and chick enzymes, while 3-aminopropanephosphonic acid, aminooxyacetic acid and nipecotic acid had a small amount of inhibitory activity on the rat enzyme only. None of the analogues tested acted as substrates for either enzyme under our conditions. Kinetic data indicated that the inhibition by APS was competitive with respect to β-alanine for both rat and chick enzymes. Inhibition of the rat enzyme by 5-AV was non-competitive with respect to β-alanine for both rat and chick enzymes. Inhibition of the rat enzyme by 5-AV was noncompetitive with respect to β-alanine. APS and 5-AV were also shown to inhibit carnosine-synthetase from rat brain and heart. Chronic injections of either APS or 5-AV failed to produce significant changes in carnosine levels in rat skeletal muscle or brain; however preliminary results indicate that APS injections may produce a lowering of carnosine levels in rat heart.     

Specific localization of scallop gill epithelial calmodulin in cilia

Calmodulin has been isolated and characterized from the gill of the bay scallop aequipecten irradians. Quantitative electrophoretic analysis of epithelial cell fractions show most of the calmodulin to be localized in the cilia, specifically in the detergent- solubilized membrane-matrix fraction. Calmodulin represents 2.2 +/- 0.3 percent of the membrane-matrix protein or 0.41 +/- 0.5 percent of the total ciliary protein. Its concentration is at least 10(-4) M if distributed uniformly within the matrix. Extraction in the presence of calcium suggests that the calmodulin is not bound to the axoneme proper. The ciliary protein is identified as a calmodulin on the basis of its calcium- dependent binding to a fluphenazine-sepharose affinity column and its comigration with bovine brain calmodulin on alkaline-urea and SDS polyacrylamide gels in both the presence and absence of calcium. Scallop ciliary calmodulin activates bovine brain phosphodiesterase to the same extent as bovine brain and chicken gizzard calmodulins. Containing trimethyllysine and lacking cysteine and tryptophan, the amino acid composition of gill calmodulin is typical of known calmodulins, except that it is relatively high in serine and low in methionine. Its composition is less acidic than other calmodulins, in agreement with an observed isoelectric point approximately 0.2 units higher than that of bovine brain. Comparative tryptic peptide mapping of scallop gill ciliary and bovine brain calmodulins indicates coincidence of over 75 percent of the major peptides, but at least two major peptides in each show no near-equivalency. Preliminary results using ATP-reactivated gill cell models show no effect of calcium at micromolar levels on ciliary beat or directionality of the lateral cilia, the cilia which constitute the vast majority of those isolated. However, ciliary arrest will occur at calcium levels more than 150 muM. Because calmodulin usually functions in the micromolar range, its role in this system is unclear. Scallop gill ciliary calmodulin may be involved in the direct regulation of dyneintubule sliding, or it may serve some coupled calcium transport function. At the concentration in which it is found, it must also at least act as a calcium buffer.     

Binding of radioactive alpha-difluoromethylornithine to rat liver ornithine decarboxylase

Inactivation of rat liver ornithine decarboxylase by incubation with [5-¹⁴C]-α-difluoromethylornithine resulted in the covalent binding of radio-activity to the enzyme. The extent of binding correlated with the degree of inactivation and with the amount of enzyme present. The labeled protein eluted as a single peak which coincided exactly with the active enzyme when chromatographed on Sephadex G-200 and ran as a single band on polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate at a position corresponding to a M.W. of about 55,000. The stoichiometric binding of [5-¹⁴C]-α-difluoromethylornithine therefore provides a convenient method for quantitating ornithine decarboxylase protein and for determining the purity of preparations of the enzyme. Assuming that 1 molecule of the drug is needed to inactivate each sub-unit, it was calculated that after stimulation with thioacetamide ornithine decarboxylase represents about 0.00014% of the liver soluble protein.     

21/21 translocation: Correlation of banding with meiotic results

Summary Meiotic studies of a boy, both of whose sibs also had Down's syndrome, were suggestive of a 21/21 chromosome rearrangement. Banding of somatic chromosomes from his mother and affected sister validated this interpredation and indicated a 21/21 translocation, not an isochromosome.

---

Zusammenfassung Meiose-Untersuchungen an einem Jungen, dessen beide Geschwister ebenfalls das Down-Syndrom hatten, ließen ein 21/21-Chromosomen-Rearrangement vermuten. Die Bandenmuster somatischer Chromosomen seiner Mutter und seiner ebenfalls kranken Schwester sprachen für diese Interpretation und wiesen auf eine 21/21-Translokation, nicht auf ein Isochromosom hin.

---

---

These studies were supported by NIH Grants AM No. 13173 and HD No. 05082 (Dr. Hecht) and RR-62 and No. 5 SO 1 RR054-11 (Dr. Seely).     

EDTA chelation therapy for cardiovascular disease: a systematic review

Background

Experimental studies support an important role for endothelial nitric oxide synthase (eNOS) in the regulation of angiogenesis. In humans, a common polymorphism exists in the eNOS gene that results in the conversion of glutamate to aspartate for codon 298. In vitro and in vivo studies have suggested a decreased NOS activity in patients with the Asp²⁹⁸ variant. We hypothesized that a genetic-mediated decreased eNOS activity may limit collateral development in patients with chronic coronary occlusions.

Methods

We selected 291 consecutive patients who underwent coronary angiography and who had at least one chronic (>15 days) total coronary occlusion. Collateral development was graded angiographically using two different methods: the collateral flow grade and the recipient filling grade. Genomic DNA was extracted from white blood cells and genotyping was performed using previously published techniques.

Results

Collateral development was lower in patients carrying the Asp²⁹⁸ variant than in Glu-Glu homozygotes (collateral flow grade: 2.64 ± 0.08 and 2.89 ± 0.08, respectively, p = 0.04; recipient filling grade: 3.00 ± 0.08 and 3.24 ± 0.07, respectively, p = 0.04). By multivariable analysis, three variables were independently associated with the collateral flow grade: female gender, smoking, and the Asp²⁹⁸ variant (p = 0.03) while the Asp²⁹⁸ variant was the sole variable independently associated with the recipient filling grade (p = 0.03).

Conclusion

Collateral development is lower in patients with the Asp²⁹⁸ variant. This may be explained by the decreased NOS activity in patients with the Asp²⁹⁸ variant. Further studies will have to determine whether increasing eNOS activity in humans is associated with coronary collateral development.     

Functional analysis of the polypyrimidine tract in pre-mRNA splicing.

The polypyrimidine tract is one of the important cis-acting sequence elements directing intron removal in pre-mRNA splicing. Progressive deletions of the polypyrimidine tract have been found to abolish correct lariat formation, spliceosome assembly and splicing. In addition, the polypyrimidine tract can alter 3'-splice site selection by promoting alternative branch site selection. However, there appears to be great flexibility in the specific sequence of a given tract. Not only the optimal composition of the polypyrimidine tract, but also the role of the tract in introns with no apparent polypyrimidine tracts or where changes in the tract are apparently harmless are uncertain. Accordingly, we have designed a series of cis-competition splicing constructs to test the functional competitive efficiency of a variety of systematically mutated polypyrimidine tracts. An RT/PCR assay was used to detect spliced product formation as a result of differential branch point selection dependent on direct competition between two opposing polypyrimidine tracts. We found that pyrimidine tracts containing 11 continuous uridines are the strongest pyrimidine tracts. In such cases, the position of the uridine stretch between the branch point and 3'-splice site AG is unimportant. In contrast, decreasing the continuous uridine stretch to five or six residues requires that the tract be located immediately adjacent to the AG for optimal competitive efficiency. The block to splicing with decreasing polypyrimidine tract strength is primarily prior to the first step of splicing. While lengthy continuous uridine tracts are the most competitive, tracts with decreased numbers of consecutive uridines and even tracts with alternating purine/pyrimidine residues can still function to promote branch point selection, but are far less effective competitors in 3'-splice site selection assays.     

The need for specialized training programs in palliative medicine

Canada faces a significant and growing burden of terminal illness. There are major unresolved economic, ethical and social issues related to care at the end of life. Despite the international reputation for Canadian efforts in palliative care, the medical profession in Canada has largely failed to recognize the importance of the field, as evidenced by the lack of commitment on the part of most medical faculties at Canadian universities to developing academic strength in palliative medicine, the lack of content in the undergraduate curriculum and of postgraduate programs in palliative medicine, and the lack of support for research into end-of-life care. The authors propose a conjoint initiative by the Royal College of Physicians and Surgeons of Canada and the College of Family Physicians of Canada to develop specialized training programs in palliative medicine as a critical step in addressing this crisis.